Scientists have found a way to “supercharge” the immune system’s natural killer (NK) cells so they can do something they usually struggle with: break into and destroy solid tumors.
Researchers at Stanford Medicine, with collaborators at Ohio State and Washington University, transformed ordinary NK cells into a tissue-resident form better at infiltrating tumors. Strikingly, they did it without genetic engineering — instead using a precise, brief exposure to a signaling molecule called TGF-β combined with direct contact with tumor cells. It was a “Goldilocks” effect: the right amount produced aggressive cancer-fighters, while too much made the cells dysfunctional. The work was published in Science Translational Medicine.
What it did
Tested against melanoma and head and neck squamous cell carcinoma, the modified NK cells infiltrated tumors far better than conventional cells and slowed tumor growth when injected into mice. Paired with the antibody drug cetuximab, a single-dose combination suppressed growth much more than either treatment alone over a month, with no apparent adverse effects.
Why it matters
Because the approach doesn’t rely on genetic engineering, the team suggests it could yield an “almost off-the-shelf” cell therapy — potentially cheaper and more accessible than today’s customized cell treatments. A Phase 1 trial is planned to begin by year’s end, pending FDA clearance. These are preclinical results, so human testing will be the real test.